Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > B-Cell Lymphomas

B-Cell Lymphomas

B-Cell Lymphomas are a diverse group of malignant lymphoid neoplasms that originate from B lymphocytes.
These cancers can arise at any stage of B-cell development and exhibit a wide range of clinical behaviors, from indolent to highly aggressive.
B-Cell Lymphomas encompass several distinct subtypes, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma, among others.
Accurate diagnosis and classification of B-Cell Lymphomas is crucial for guiding appropriate treatment strategies and improving patient outcomes.
Reasearch in this area continues to advance our understading of the molecular pathogenesis and optimal management of these complex hematologic malignancies.

Most cited protocols related to «B-Cell Lymphomas»

1
Comparative Analysis of circRNA Identification Algorithms
Ribominus RNA-seq data for four cell types (SRP009373, CD19+, CD34+, neutrophils; SRR650317, HEK293) generated in two circRNA-related studies [11 (link),13 (link)] were downloaded from the NCBI SRA database. Data sets from both studies comprise paired-end sequencing data, though read lengths are different. Read mapping was performed using BWA-MEM with default parameters except '-T 19'. The SAM alignment records for the two data sets were subsequently analyzed by CIRI separately using PE mode (-p), low stringency (-low), max spanning distance 500 kb (-m 500,000) and Gencode version 18 GTF annotation (-a). We incorporated the outputs to compare them with the prediction results of Memczak et al. [11 (link)] using a custom script. We also applied CIRI to 15 RNA-seq data sets generated by the ENCODE project and used for circRNA analysis in a more recent report [7 (link)]. BWA-MEM and CIRI parameters were the same as described above except for mapping quality thresholds for each segment (-u 3) and total of segments (-b 13) of a candidate junction read. Eleven (SRR060824, SRR192530, SRR192531, SRR765631-SRR765637 and ch12: B-cell lymphoma) out of 18 data sets in the study of Guo et al. [16 (link)] were used for identification of mouse circRNAs. CIRI parameters were default settings except for SE mode for single-end data. GTF annotation and genome sequences were downloaded from [31 ] using the latest versions. We incorporated the outputs to compare them with the prediction results of Guo et al. [16 (link)] using a custom script. Mapping details of candidate circRNAs predicted by the above algorithms were checked using the visual mapping tools inGAP and inGAP-sv [32 ,33 (link)].
Gao Y., Wang J, & Zhao F. (2015). CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biology, 16(1), 4.
Publication 2015
B-Cell Lymphomas Cells Genome Mus Neutrophil proIslet peptide, human RNA, Circular RNA-Seq
2
Harmonization of AQP4-Ab Assays for NMO
All centres were asked to provide sera or plasma samples from 8 to 10 patients with AQP4-antibody positive or negative NMO or NMOSDs, excluding cases with unclear diagnoses or diagnoses complicated by related pathologies, and a similar number of clearly defined neurological control samples (eg, MS, other inflammatory neurological disease). Four groups provided samples only, whereas 15 groups performed assays only, and 6 groups provided samples and performed assays. A total of 209 coded sera/plasma samples were received by Euroimmun AG, Germany from 10 centres by May 2013 (16 were excluded due to insufficient volume, figure 1, table 1). The controls comprised samples from patients with a headache (39), MS (35 relapsing remitting, 2 primary progressive19 (link)), clinically isolated syndromes (4, all exhibited clinical and paraclinical features typical of MS), tumour (1 B-cell lymphoma, 1 colon carcinoma with neurological complications), Susac syndrome (1), progressive encephalomyelitis with rigidity and myoclonus (1), neuromyotonia (1), connective tissue disorder (1), myasthenia gravis (MG) (5) and acute disseminated encephalomyelitis (120 (link)). The test samples comprised 50 samples from patients who fulfilled the 2006 diagnostic criteria for NMO16 (link) excluding AQP4 serostatus (35 submitted as seropositive from different centres based on their different AQP4 assays), and 51 samples were from patients with clinical features of NMO who did not meet the criteria (9 ON, 31 TM, and 11 with ON and TM; 39 submitted as seropositive by the centres; these were referred to as NMOSD in the context of this study). The NMO/spectrum disorder (SD) cohort was predominantly female (4.6:1) with a median age at sampling of 45 years and the samples were taken at a median of 3 years (range 0–30 years) from disease onset, mostly during remission (3·35:1).
Waters P., Reindl M., Saiz A., Schanda K., Tuller F., Kral V., Nytrova P., Sobek O., Nielsen H.H., Barington T., Lillevang S.T., Illes Z., Rentzsch K., Berthele A., Berki T., Granieri L., Bertolotto A., Giometto B., Zuliani L., Hamann D., van Pelt E.D., Hintzen R., Höftberger R., Costa C., Comabella M., Montalban X., Tintoré M., Siva A., Altintas A., Deniz G., Woodhall M., Palace J., Paul F., Hartung H.P., Aktas O., Jarius S., Wildemann B., Vedeler C., Ruiz A., Leite M.I., Trillenberg P., Probst M., Saschenbrecker S., Vincent A, & Marignier R. (2016). Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery, and Psychiatry, 87(9), 1005-1015.
Publication 2016
B-Cell Lymphomas Biological Assay Cancer of Colon Connective Tissue Diseases Diagnosis Encephalomyelitis, Acute Disseminated Headache Immunoglobulins Inflammation Isaacs' Syndrome Myasthenia Gravis Myoclonus Neoplasms Nervous System Disorder Neuromyelitis Optica Patients Plasma Progressive Encephalomyelitis with Rigidity Serum Susac Syndrome Syndrome Woman
3
Metabolic Profiling of Hypoxic Lymphoma Cells

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Atmosphere B-Cell Lymphomas Cells Glucose Glutamine Homo sapiens Hypoxia Plasma
4
Genetic Predictors of Breast Biopsy
Women referred for breast biopsies at the Hospital of the University of Pennsylvania following a BI-RADS 4 mammogram between January 2010 and April 2012 were invited to participate in the study. Women were excluded if they were younger than 20 years old, had a personal history of breast or ovarian cancer, mantle radiation or known BRCA1/2 mutation. Women who consented provided a buccal swab for DNA testing prior to their biopsy appointment. Three hundred sixty-three women were enrolled. An additional 119 women with a BI-RADS 4 mammograms from a previous study in which breast imaging modalities were compared at the same institution were also included (2002 to 2006; National Institutes of Health grant P01 CA85484; Principal Investigator: M Schnall). Participants in the breast imaging study were enrolled between July 2003 and August 2007. A blood sample from each patient was collected and stored, which was used for genetic analysis. Of the total sample, five patients were missing follow-up information, eleven had data on fewer than nine SNP markers and two had nonbreast malignancies (tubular adenoma, B-cell lymphoma in the breast). These participants were excluded, resulting in a total population of 464 for analysis. Both studies were approved by the University of Pennsylvania Institutional Review Board, and written informed consent was obtained from each study participant.
McCarthy A.M., Keller B., Kontos D., Boghossian L., McGuire E., Bristol M., Chen J., Domchek S, & Armstrong K. (2015). The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. Breast Cancer Research : BCR, 17(1), 1.
Publication 2015
Adenoma B-Cell Lymphomas Biopsy BLOOD BRCA1 protein, human Breast DNA, A-Form Ethics Committees, Research Malignant Neoplasms Mammography Mutation Ovarian Cancer Patients Radiotherapy RRAD protein, human Woman Youth
5
Axi-cel CAR T-cell Therapy for Refractory B-cell Lymphoma
The study was approved by the institutional review board at each study site and was conducted in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonisation. All the patients provided written informed consent. The study was designed by employees of Kite Pharma, which also paid for medical-writing support. All the authors discussed and interpreted the results and vouch for the completeness and accuracy of the data and analyses and for the adherence of the study to the protocol, available with the full text of this article at NEJM.org. All the authors contributed to the conduct of the study, data analyses, and writing of the manuscript.
The phase 2 treatment portion of the study ran from November 2015 through September 2016 at 22 study centers (21 in the United States and 1 in Israel). (A complete list of study sites is provided in the Supplementary Appendix, available at NEJM.org.) Follow-up to evaluate the duration of response, survival, and late adverse events is ongoing.
All the patients had histologically confirmed large B-cell lymphoma, including diffuse large B-cell lymphoma (cohort 1) and primary mediastinal B-cell lymphoma or transformed follicular lymphoma (cohort 2), on the basis of the 2008 World Health Organization guidelines.22 Central confirmation of the diagnosis was performed retrospectively. Patients had refractory disease, which was defined as progressive or stable disease as the best response to the most recent chemotherapy regimen or disease progression or relapse within 12 months after autologous stem-cell transplantation. Eligibility criteria and therapy were similar to those in the phase 1 study (see the Methods section in the Supplementary Appendix).21 (link)After leukapheresis and axi-cel manufacturing, patients received fixed low-dose conditioning chemotherapy consisting of fludarabine (at a dose of 30 mg per square meter of body-surface area per day) and cyclophosphamide (at a dose of 500 mg per square meter per day) on days −5, −4, and −3 before the administration of a single intravenous infusion of axi-cel at a target dose of 2×106 CAR T cells per kilogram of body weight (on day 0).21 (link) Systemic bridging chemotherapy was not allowed after leukapheresis and before the administration of axi-cel. Patients who had an initial response and then had disease progression at least 3 months after the first dose of axi-cel could be retreated.
Neelapu S.S., Locke F.L., Bartlett N.L., Lekakis L.J., Miklos D.B., Jacobson C.A., Braunschweig I., Oluwole O.O., Siddiqi T., Lin Y., Timmerman J.M., Stiff P.J., Friedberg J.W., Flinn I.W., Goy A., Hill B.T., Smith M.R., Deol A., Farooq U., McSweeney P., Munoz J., Avivi I., Castro J.E., Westin J.R., Chavez J.C., Ghobadi A., Komanduri K.V., Levy R., Jacobsen E.D., Witzig T.E., Reagan P., Bot A., Rossi J., Navale L., Jiang Y., Aycock J., Elias M., Chang D., Wiezorek J, & Go W.Y. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of medicine, 377(26), 2531-2544.
Publication 2017
3-acetonylidene-2-oxindole B-Cell Lymphomas Body Surface Area Body Weight Conferences Cyclophosphamide Diagnosis Diffuse Large B-Cell Lymphoma Disease Progression Eligibility Determination Ethics Committees, Research fludarabine Intravenous Infusion Leukapheresis Lymphoma, Follicular Mediastinum Patients Pharmacotherapy Ran 2 protein, rat Relapse Reticulosarcoma T-Lymphocyte Therapeutics Transplantations, Stem Cell Treatment Protocols Vitelliform Macular Dystrophy

Most recents protocols related to «B-Cell Lymphomas»

1
Lymphoma Stromal Cells Promote Tumor Growth
Not available on PMC !

Example 8

Lymphoma Stromal Cells (LSCs) Promote Lymphoma Development in a NO-Dependent Manner

To examine the effect of lymphoma stromal cells on tumor growth, 355 B-cell lymphoma cell line (C3H-gld/gld background, 0.5×106 cells/mouse) was co-injected with gld/gld mice-derived lymphoma stromal cells (C3H background, P5, 0.25×106 cells/mouse). It was observed that co-injection of stromal cells significantly enhanced the mortality. Interestingly, administration of 1400 W (NOS inhibitor, 0.1 mg/mouse on day 0, 2, 4, 8, 12, 16, 20, 24, and 28) significantly reverted the effect (FIG. 4). Therefore, the tumor stromal cells could significantly promote tumor growth.

US11872250B2. Methods for inducing an immune response by administering activated mesenchymal stem cells (2024-01-16). Rutgers, The State University of New Jersey [US]. Inventors: Yufang Shi [US], Guangwen Ren [US], Liying Zhang [US].
Patent 2024
1400 W B-Cell Lymphomas Cells Lymphoma Mesenchymal Stem Cells Mesenchymal Stromal Cells Mus Neoplasms Response, Immune Stem Cells Stromal Cells
2
Western Blot Analysis of Apoptosis and Oxidative Stress Markers
H9c2 cardiomyocytes from each group were collected and total protein was extracted after cell lysis in RIPA buffer (Protech Technology Enterprise Co., Ltd.) at 4˚C for 20 min, followed by centrifugation at 8,798 x g for 10 min at 4˚C. Protein concentration was measured using a BCA kit (cat. no. A045-4-2; Nanjing Jiancheng Bioengineering Institute). Total protein extract from each group (20 µg/lane) was separated by SDS-PAGE on a 10% gel and transferred onto PVDF membranes (EMD Millipore). Following blocking with 5% skimmed milk for 2 h at room temperature, membranes were incubated with the following primary antibodies at 4˚C overnight: Anti-B-cell lymphoma 2 (Bcl-2; cat. no. ab196495; 1:1,000); anti-Bcl-2-associated X protein (Bax; cat. no. ab32503; 1:1,000); anti-poly(ADP-ribose) polymerase (PARP; cat. no. ab191217; 1:1,000); anti-cleaved PARP (cat. no. ab32064; 1:1,000); anti-Nrf2 (cat. no. ab92946; 1:1,000) and anti-HO-1 (cat. no. ab189491; 1:2,000; all Abcam); anti-phosphorylated (p)-NF-κB (cat. no. 3033; 1:1,000) and anti-NF-κB (cat. no. 8242; 1:1,000; both Cell Signaling Technology, Inc.) and β-actin (cat. no. ab8227; 1:1,000; Abcam). The membranes were incubated with corresponding horseradish peroxidase-conjugated secondary antibody (cat. no. ab6721; 1:2,000; Abcam) for 1 h at room temperature. The protein bands were visualized using ECL Western Blotting Substrate (Pierce; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Densitometry analysis was performed using ImageJ 1.52a software (National Institutes of Health) with β-actin as the loading control.
Wang W, & Shen Q. (2023). Tranilast reduces cardiomyocyte injury induced by ischemia‑reperfusion via Nrf2/HO‑1/NF‑κB signaling. Experimental and Therapeutic Medicine, 25(4), 160.
Publication 2023
Actins Antibodies B-Cell Lymphomas Bax Protein BCL2 protein, human Buffers Centrifugation Densitometry Horseradish Peroxidase Immunoglobulins Milk, Cow's Myocytes, Cardiac NFE2L2 protein, human Poly(ADP-ribose) Polymerases polyvinylidene fluoride Proteins Radioimmunoprecipitation Assay RELA protein, human SDS-PAGE Tissue, Membrane
3
Flow Cytometry Screening for Mature B-cell Lymphomas
Mature B-cell lymphoproliferative disease in patients >30yrs was screened by monoclonal antibodies mixed with CD45-V500c, CD19-Pacific Blue, CD20-APC, CD38-PerCP-Cy5.5, CD10-PE-Cy7, kappa-FITC, and lambda-PE. B-cell and plasma cells in patients >30yrs were screened with a tube containing CD45-V500c, CD19-Pacific Blue, CD20-APC-Cy7, CD38-PerCP-Cy5.5, CD56-ECD, CD138-APC, cytoplasmic κ-FITC, and cytoplasmic λ-PE. The samples were all stained with these T- and B-cell lymphatic screening tubes.
This article uses a method of MFC sample staining and panel screening (14 (link)). If the screening tube detected that the B lymphocytes had an abnormal immunophenotype, we continued to label fluorescent antibody Ki67; Kappa-FITC/Lambda-PE were purchased from DAKO; CD19-Pacific Blue, and CD20-Pacific Blue were purchased from Biolegend. The BD Pharmingen FITC Mouseanti-Ki67 Set (Clone: B56) is compatible with the BD IntraSure™ Kit (641776), and the remainder was purchased from the Becton Dickinson Company (BD, San Jose, CA). Intracellular staining with Ki67 was performed according to the manufacturer’s instructions. At least 5000 abnormal CDl9+ B lymphocytes or a total of 3×105 white blood cells were obtained from each tube. The abnormal B lymphocyte population was gated by CD45/SSC, CDl9/SSC, CDl9/FSC, CD20/SSC, and CDl9/CD20, and the positive rate of Ki67 in these cells was analyzed. The gating strategy for detecting the positive rate of Ki67 expression in non-Hodgkin B-cell lymphoma by flow cytometry is shown in the Supplementary Figure. Abnormal B lymphocytes were defined as populations of CDl9+ or CD20+ cells restricted by Kappa or lambda immunoglobulin light chain expression (or double-negative), abnormal scattered light such as alterations in forwarding scattered light (FSC) and (or) side scattered light (SSC), and abnormal B lymphocytes were often associated with abnormal expression of other antigens, such as CLL cells CD5+CD23+CD20dimCD22dimCD79dim (15 (link)). Specimens were analyzed on a BDIS FACSFortessa MFC system from the Becton Dickinson Company and Diva software was used for analysis (BD Biosciences, San Jose, CA).
Mao X., Li Y., Liu S., He C., Yi S., Kuang D., Xiao M., Zhu L, & Wang C. (2023). Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms. Frontiers in Oncology, 13, 1108837.
Publication 2023
Antigens B-Cell Lymphomas B-Lymphocytes Cells Clone Cells CY5.5 cyanine dye Cytoplasm Flow Cytometry Fluorescein-5-isothiocyanate Fluorescent Antibody Technique Immunoglobulin lambda-Chains Immunophenotyping Leukocytes Light Lymphoproliferative Disorders Monoclonal Antibodies Patients Plasma Cells Population Group Protoplasm SDC1 protein, human
4
Retrospective Analysis of Mature B-cell Neoplasms
Flow cytometric results from patients who were diagnosed with mature B-cell neoplasms from October 2015 to October 2020, were reviewed retrospectively. Each case represented a primary diagnosis of lymphoma that was made based on an incisional or excisional tissue biopsy or fine-needle aspiration biopsy specimens. Histologic slides including immunohistochemical slides, were reviewed without knowledge of the flow cytometric results to confirm the initial diagnoses in all available cases. The diagnosis was made according to the World Health Organization (WHO) 2008 classification (12 (link)), WHO 2017 classification,and WHO 2022 classification (2 , 3 (link), 13 (link)). These patients included 119 patients with DLBCL, 25 patients with Burkitt lymphoma, 67 patients with MCL, 76 patients with follicular lymphoma (FL), 30 patients with marginal zone lymphoma (MZL), 32 patients with lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM), 159 patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), 5 patients with hairy cell leukemia, 4 patients with mucosa-associated lymphoid tissue lymphoma (MALT-L), and 42 patients with transformed lymphoma. For the diagnosis, Ki67 expression in lymphoma cells was detected in the bone marrow, pleural effusion, and ascites or lymph node samples. The present study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, and Huazhong University of Science and Technology (permit number TJ-IRB20200716), and all procedures conducted followed the protocols of the Declaration of Helsinki.
Mao X., Li Y., Liu S., He C., Yi S., Kuang D., Xiao M., Zhu L, & Wang C. (2023). Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms. Frontiers in Oncology, 13, 1108837.
Publication 2023
Ascites Aspiration Biopsy, Fine-Needle B-Cell Lymphomas Biopsy Bone Marrow Burkitt Lymphoma Cells Chronic Lymphocytic Leukemia Diagnosis Flow Cytometry Hairy Cell Leukemia Lymphoma Lymphoma, Follicular Mucosa-Associated Lymphoid Tissue Lymphoma Nodes, Lymph Patients Pleural Effusion Tissues Waldenstrom Macroglobulinemia
5
Western Blot Analysis of Protein Expression
Cells were lysed using RIPA lysis buffer (Thermo-Fisher Scientific) supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo-Fisher Scientific). Protein concentrations were measured by using a Detergent Compatible protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and the same amount of protein was loaded into a 4–15% NuPAGE Bis–Tris Protein gel. Gels were transferred using an iBlot Dry blotting system onto nitrocellulose membranes (Thermo-Fisher Scientific), and the transferred samples were blocked for 1 h at RT in 5% non-fat-dry-milk in tris-buffered saline (TBS). Primary antibodies used included: Phospho-MLKL (Cat# 916,895, Cell Signaling, Danvers, MA), Mixed Lineage Kinase Domain Like Pseudokinase (MLKL) (Cat #14993S, Cell Signaling), and B cell lymphoma (Bcl)-2 (Cat#Ab182858, Abcam, Cambridge, UK). Images of chemiluminescent bands were acquired using a Bio-Rad Gel documentation system (Bio-Rad Laboratories, Inc.). Membranes were washed in TBS-T, blotted with anti-tubulin antibody (Abcam CAT#Ab6046), and developed similarly. Image Lab Software version 6.0.1 (Bio-Rad Laboratories, Inc.) was used to perform densitometric analysis. Results were expressed as fold-change compared to control cells.
Badaro-Garcia S., Hohmann M.S., Coelho A.L., Verri WA J.r, & Hogaboam C.M. (2023). Standard of care drugs do not modulate activity of senescent primary human lung fibroblasts. Scientific Reports, 13, 3654.
Publication 2023
Antibodies Antibodies, Anti-Idiotypic B-Cell Lymphomas Biological Assay Bistris Buffers Cells Densitometry Detergents MAP3K13 protein, human Milk, Cow's Nitrocellulose Peptide Hydrolases Phosphoric Monoester Hydrolases Proteins Radioimmunoprecipitation Assay Saline Solution Staphylococcal Protein A Tissue, Membrane Tubulin

Top products related to «B-Cell Lymphomas»

1
Ab32503 by Abcam
Sourced in United States, United Kingdom, China
Ab32503 is a laboratory equipment product manufactured by Abcam. It serves as a core function in research and scientific experiments, but a detailed description cannot be provided while maintaining an unbiased and factual approach.
2
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
3
Pvdf membrane by Merck Group
Sourced in United States, Germany, China, United Kingdom, Morocco, Ireland, France, Italy, Japan, Canada, Spain, Switzerland, New Zealand, India, Hong Kong, Sao Tome and Principe, Sweden, Netherlands, Australia, Belgium, Austria
PVDF membranes are a type of laboratory equipment used for a variety of applications. They are made from polyvinylidene fluoride (PVDF), a durable and chemically resistant material. PVDF membranes are known for their high mechanical strength, thermal stability, and resistance to a wide range of chemicals. They are commonly used in various filtration, separation, and analysis processes in scientific and research settings.
4
Ab32124 by Abcam
Sourced in United States, United Kingdom, China, Japan
Ab32124 is a protein-based lab equipment product. It is designed for use in research applications. The core function of this product is to facilitate the study and analysis of biological samples.
5
Cleaved caspase 3 by Cell Signaling Technology
Sourced in United States, United Kingdom, China, Germany, Canada, Japan, Morocco, Denmark, Switzerland, France, Netherlands, Macao
Cleaved caspase-3 is an antibody that detects the activated form of caspase-3 protein. Caspase-3 is a key enzyme involved in the execution phase of apoptosis, or programmed cell death. The cleaved caspase-3 antibody specifically recognizes the active, cleaved form of the enzyme and can be used to monitor and quantify apoptosis in experimental systems.
6
Trizol reagent by Thermo Fisher Scientific
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
7
Bcl 2 by Cell Signaling Technology
Sourced in United States, China, United Kingdom, Germany, Canada, Japan, Italy, India
Bcl-2 is a protein that plays a key role in regulating apoptosis, or programmed cell death. It functions as an anti-apoptotic protein, helping to prevent cell death by inhibiting the activity of pro-apoptotic proteins.
8
Ab205718 by Abcam
Sourced in United States, United Kingdom, China, France, Japan
Ab205718 is a lab equipment product from Abcam. It is a core laboratory instrument used for various analytical and experimental procedures.
9
Ab2302 by Abcam
Sourced in United States, United Kingdom, China
Ab2302 is a laboratory consumable product manufactured by Abcam. It is designed to facilitate specific research applications, but a detailed description of its core function cannot be provided while maintaining an unbiased and factual approach. Further information about the intended use of this product is not available.
10
β actin by Merck Group
Sourced in United States, United Kingdom, Germany, China, Canada, Japan, Macao, Italy, Sao Tome and Principe, Israel, Spain, Denmark, France, Finland, Australia, Morocco, Ireland, Czechia, Sweden, Uruguay, Switzerland, Netherlands, Senegal
β-actin is a protein that is found in all eukaryotic cells and is involved in the structure and function of the cytoskeleton. It is a key component of the actin filaments that make up the cytoskeleton and plays a critical role in cell motility, cell division, and other cellular processes.

More about "B-Cell Lymphomas"

B-Cell Lymphomas, also known as B-cell neoplasms, are a diverse group of hematologic malignancies that originate from abnormal B lymphocytes.
These cancers can arise at various stages of B-cell development and exhibit a wide spectrum of clinical behaviors, ranging from indolent to highly aggressive.
The major subtypes of B-Cell Lymphomas include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Accurate diagnosis and classification of these subtypes is crucial for guiding appropriate treatment strategies and improving patient outcomes.
B-Cell Lymphomas can be characterized by various molecular and immunohistochemical markers, such as Bcl-2, a protein involved in the regulation of apoptosis, and β-actin, a commonly used housekeeping gene for normalization in Western blot analysis.
The TRIzol reagent is often used for RNA extraction, while PVDF membranes are commonly employed in Western blotting techniques to study the expression of proteins like Cleaved caspase-3, a marker of apoptosis.
Ongoing research in this field continues to advance our understanding of the molecular pathogenesis and optimal management of these complex hematologic malignancies.
For example, studies have explored the use of Ab32503 and Ab32124, which are antibodies that can be used to detect specific protein targets in B-Cell Lymphomas.
Additionally, the Ab205718 and Ab2302 antibodies may be utilized in various immunoassays and imaging techniques to further elucidate the underlying mechanisms of these cancers.
PubCompare.ai, an AI-driven platform, can enhance B-Cell Lymphoma research by streamlining the process of locating and comparing relevant protocols from the literature, preprints, and patents.
This tool can help researchers identify the most effective protocols and products for their studies, ultimately accelerating the advancement of our understanding and treatment of these complex hematologic malignancies.